
Tetra Bio-Pharma Inc. – TSX:TBP.TO
Tetra Bio-Pharma stock price today
Tetra Bio-Pharma stock price quarterly change
Tetra Bio-Pharma stock price yearly change
Tetra Bio-Pharma key metrics
Market Cap | 10.58M |
Enterprise value | 11.76M |
P/E | -0.31 |
EV/Sales | N/A |
EV/EBITDA | -1.39 |
Price/Sales | N/A |
Price/Book | -1.79 |
PEG ratio | N/A |
EPS | -0.09 |
Revenue | N/A |
EBITDA | -11.80M |
Income | -39.36M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTetra Bio-Pharma stock price history
Tetra Bio-Pharma stock forecast
Tetra Bio-Pharma financial statements
Nov 2021 | 0 | -30.18M | |
---|---|---|---|
Feb 2022 | 0 | -1.76M | |
May 2022 | 0 | -3.82M | |
Aug 2022 | 0 | -3.59M |
Nov 2021 | 7551242 | 7.30M | 96.7% |
---|---|---|---|
Feb 2022 | 8795238 | 8.26M | 94.01% |
May 2022 | 4927674 | 7.51M | 152.49% |
Aug 2022 | 3019633 | 8.92M | 295.68% |
Nov 2021 | -3.00M | -683.75K | -1.5M |
---|---|---|---|
Feb 2022 | -2.39M | 0 | 1.17M |
May 2022 | -1.91M | 0 | -18.18K |
Aug 2022 | -873.52K | 0 | -378.46K |
Tetra Bio-Pharma alternative data
Aug 2023 | 33 |
---|---|
Sep 2023 | 33 |
Oct 2023 | 33 |
Nov 2023 | 33 |
Dec 2023 | 33 |
Jan 2024 | 33 |
Feb 2024 | 33 |
Mar 2024 | 33 |
Apr 2024 | 33 |
May 2024 | 33 |
Jun 2024 | 33 |
Jul 2024 | 33 |
Tetra Bio-Pharma other data
Insider | Compensation |
---|---|
Dr. Guy Chamberland M.Sc., Master Herbal, Ph.D. (1962) Co-Founder, Chief Executive Officer, Chief Regulatory Officer & Director | $447,650 |
-
What's the price of Tetra Bio-Pharma stock today?
One share of Tetra Bio-Pharma stock can currently be purchased for approximately $0.13.
-
When is Tetra Bio-Pharma's next earnings date?
Unfortunately, Tetra Bio-Pharma's (TBP.TO) next earnings date is currently unknown.
-
Does Tetra Bio-Pharma pay dividends?
No, Tetra Bio-Pharma does not pay dividends.
-
How much money does Tetra Bio-Pharma make?
Tetra Bio-Pharma has a market capitalization of 10.58M.
-
What is Tetra Bio-Pharma's stock symbol?
Tetra Bio-Pharma Inc. is traded on the TSX under the ticker symbol "TBP.TO".
-
What is Tetra Bio-Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Tetra Bio-Pharma?
Shares of Tetra Bio-Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Tetra Bio-Pharma's key executives?
Tetra Bio-Pharma's management team includes the following people:
- Dr. Guy Chamberland M.Sc., Master Herbal, Ph.D. Co-Founder, Chief Executive Officer, Chief Regulatory Officer & Director(age: 63, pay: $447,650)
-
Is Tetra Bio-Pharma founder-led company?
Yes, Tetra Bio-Pharma is a company led by its founder Dr. Guy Chamberland M.Sc., Master Herbal, Ph.D..
-
How many employees does Tetra Bio-Pharma have?
As Jul 2024, Tetra Bio-Pharma employs 33 workers.
-
When Tetra Bio-Pharma went public?
Tetra Bio-Pharma Inc. is publicly traded company for more then 7 years since IPO on 10 Jul 2018.
-
What is Tetra Bio-Pharma's official website?
The official website for Tetra Bio-Pharma is tetrabiopharma.com.
-
Where are Tetra Bio-Pharma's headquarters?
Tetra Bio-Pharma is headquartered at 2316 St. Joseph Boulevard, Orléans, ON.
-
How can i contact Tetra Bio-Pharma?
Tetra Bio-Pharma's mailing address is 2316 St. Joseph Boulevard, Orléans, ON and company can be reached via phone at +34 37802020.
Tetra Bio-Pharma company profile:

Tetra Bio-Pharma Inc.
tetrabiopharma.comTSX
33
Biotechnology
Healthcare
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. The company is headquartered in Orléans, Canada.
Orléans, ON K1C 1E8
:
ISIN: CA88166Y1007
: